GMED
Price
$82.63
Change
+$0.69 (+0.84%)
Updated
Dec 20 closing price
60 days until earnings call
MYGN
Price
$13.36
Change
+$0.19 (+1.44%)
Updated
Dec 20 closing price
72 days until earnings call
Ad is loading...

GMED vs MYGN

Header iconGMED vs MYGN Comparison
Open Charts GMED vs MYGNBanner chart's image
Globus Medical
Price$82.63
Change+$0.69 (+0.84%)
Volume$2.83M
CapitalizationN/A
Myriad Genetics
Price$13.36
Change+$0.19 (+1.44%)
Volume$3.97M
CapitalizationN/A
GMED vs MYGN Comparison Chart
Loading...
GMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMED vs. MYGN commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and MYGN is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (GMED: $82.63 vs. MYGN: $13.36)
Brand notoriety: GMED and MYGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GMED: 282% vs. MYGN: 395%
Market capitalization -- GMED: $7.19B vs. MYGN: $1.93B
GMED [@Medical Specialties] is valued at $7.19B. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMED’s FA Score shows that 1 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • GMED’s FA Score: 1 green, 4 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, GMED is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMED’s TA Score shows that 3 TA indicator(s) are bullish while MYGN’s TA Score has 2 bullish TA indicator(s).

  • GMED’s TA Score: 3 bullish, 4 bearish.
  • MYGN’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, GMED is a better buy in the short-term than MYGN.

Price Growth

GMED (@Medical Specialties) experienced а +0.25% price change this week, while MYGN (@Medical Specialties) price change was -7.42% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.49%. For the same industry, the average monthly price growth was +1.84%, and the average quarterly price growth was +2.97%.

Reported Earning Dates

GMED is expected to report earnings on Feb 20, 2025.

MYGN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Medical Specialties (-1.49% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMED($7.19B) has a higher market cap than MYGN($1.93B). GMED YTD gains are higher at: 55.057 vs. MYGN (-30.199). GMED has higher annual earnings (EBITDA): 347M vs. MYGN (-197.4M). GMED has more cash in the bank: 518M vs. MYGN (141M). MYGN has less debt than GMED: MYGN (152M) vs GMED (520M). GMED has higher revenues than MYGN: GMED (1.57B) vs MYGN (753M).
GMEDMYGNGMED / MYGN
Capitalization7.19B1.93B373%
EBITDA347M-197.4M-176%
Gain YTD55.057-30.199-182%
P/E Ratio49.65N/A-
Revenue1.57B753M208%
Total Cash518M141M367%
Total Debt520M152M342%
FUNDAMENTALS RATINGS
GMED vs MYGN: Fundamental Ratings
GMED
MYGN
OUTLOOK RATING
1..100
7760
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
8597
PRICE GROWTH RATING
1..100
4191
P/E GROWTH RATING
1..100
41
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GMED's Valuation (87) in the Medical Specialties industry is in the same range as MYGN (95) in the Biotechnology industry. This means that GMED’s stock grew similarly to MYGN’s over the last 12 months.

GMED's Profit vs Risk Rating (46) in the Medical Specialties industry is somewhat better than the same rating for MYGN (100) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than MYGN’s over the last 12 months.

GMED's SMR Rating (85) in the Medical Specialties industry is in the same range as MYGN (97) in the Biotechnology industry. This means that GMED’s stock grew similarly to MYGN’s over the last 12 months.

GMED's Price Growth Rating (41) in the Medical Specialties industry is somewhat better than the same rating for MYGN (91) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is in the same range as GMED (4) in the Medical Specialties industry. This means that MYGN’s stock grew similarly to GMED’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMEDMYGN
RSI
ODDS (%)
Bearish Trend 3 days ago
56%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
56%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
56%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
58%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
78%
View a ticker or compare two or three
Ad is loading...
GMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME29.820.82
+2.83%
GameStop Corp
AAPL254.494.70
+1.88%
Apple
SPY591.157.02
+1.20%
SPDR® S&P 500® ETF Trust
BTC.X97224.730000-531.203100
-0.54%
Bitcoin cryptocurrency
TSLA421.06-15.11
-3.46%
Tesla

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with ATEC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then ATEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+0.84%
ATEC - GMED
45%
Loosely correlated
+5.65%
EMBC - GMED
40%
Loosely correlated
+1.30%
OFIX - GMED
38%
Loosely correlated
+1.40%
MYGN - GMED
37%
Loosely correlated
+1.44%
FNA - GMED
34%
Loosely correlated
+2.35%
More

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with TMO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
+1.44%
TMO - MYGN
39%
Loosely correlated
+1.42%
WAT - MYGN
39%
Loosely correlated
+2.09%
GMED - MYGN
37%
Loosely correlated
+0.84%
VCYT - MYGN
36%
Loosely correlated
+4.66%
ILMN - MYGN
35%
Loosely correlated
+1.51%
More